Crohn's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Crohn's Disease, including details on symptoms, diagnosis, treatment, causes, medication.

Volume 4 (2007), Issue 5 (May)

1. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study.
   Hepatology, 45(5): 1267-74. [Abstract] [Full-text]
2. Statistical models for haplotype sharing in case-parent trio data.
   Hum Hered, 64(1): 35-44. [Abstract] [Full-text]
3. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
   Gastroenterology, 132(5): 1672-83. [Abstract] [Full-text]
4. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5.
   Gastroenterology, 132(5): 1665-71. [Abstract] [Full-text]
5. Evaluating appropriateness of treatment for Crohn's disease: feasibility of an explicit approach.
   Digestion, 75(1): 46-52. [Abstract] [Full-text]
6. Impact of enteral supplements enriched with omega-3 fatty acids and/or omega-6 fatty acids, arginine and ribonucleic acid compounds on leptin levels and nutritional status in active Crohn's disease treated with prednisolone.
   Digestion, 75(1): 10-6. [Abstract] [Full-text]
7. Inflammatory bowel disease: clinical aspects and established and evolving therapies.
   Lancet, 369(9573): 1641-57. [Abstract] [Full-text]
8. The NOD2-RICK complex signals from the plasma membrane.
   J Biol Chem, 282(20): 15197-207. [Abstract] [Full-text]
9. Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts.
   Inflamm Bowel Dis, 13(5): 573-9. [Abstract] [Full-text]
10. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease.
    Inflamm Bowel Dis, 13(5): 511-5. [Abstract] [Full-text]
11. MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease.
    Inflamm Bowel Dis, 13(5): 585-90. [Abstract] [Full-text]
12. Growth retardation in pediatric Crohn's disease: pathogenesis and interventions.
    Inflamm Bowel Dis, 13(5): 620-8. [Abstract] [Full-text]
13. Increased subpopulations of CD16(+) and CD56(+) blood monocytes in patients with active Crohn's disease.
    Inflamm Bowel Dis, 13(5): 566-72. [Abstract] [Full-text]
14. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations.
    Inflamm Bowel Dis, 13(5): 524-30. [Abstract] [Full-text]
15. Potential role for the common cystic fibrosis DeltaF508 mutation in Crohn's disease.
    Inflamm Bowel Dis, 13(5): 531-6. [Abstract] [Full-text]
16. Contribution of genetic and environmental factors in the pathogenesis of Crohn's disease in a large family with multiple cases.
    Inflamm Bowel Dis, 13(5): 580-4. [Abstract] [Full-text]
17. Inflammatory bowel diseases: meeting of the European Crohn's Colitis Organization, 1-3 March 2007, Innsbruck, Austria.
    Expert Opin Ther Targets, 11(6): 853-6. [Abstract] [Full-text]
18. Ultrastructural injury to interstitial cells of Cajal and communication with mast cells in Crohn's disease.
    Neurogastroenterol Motil, 19(5): 349-64. [Abstract] [Full-text]
19. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4.
    PLoS Genet, 3(4): e58. [Abstract] [Full-text]
20. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.
    Inflamm Bowel Dis, 13(4): 372-9. [Abstract] [Full-text]
21. Clinical epidemiology of inflammatory bowel disease in Lebanon.
    Inflamm Bowel Dis, 13(4): 475-80. [Abstract] [Full-text]
22. Oral biopsies from patients with orofacial granulomatosis with histology resembling Crohn's disease have a prominent Th1 environment.
    Inflamm Bowel Dis, 13(4): 439-45. [Abstract] [Full-text]
23. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark.
    Inflamm Bowel Dis, 13(4): 481-9. [Abstract] [Full-text]
24. Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease.
    Inflamm Bowel Dis, 13(4): 391-7. [Abstract] [Full-text]
25. Health-related quality of life after ileocolonic resection for Crohn's disease: long-term results.
    Inflamm Bowel Dis, 13(4): 462-9. [Abstract] [Full-text]
26. Active and passive smoking in childhood is related to the development of inflammatory bowel disease.
    Inflamm Bowel Dis, 13(4): 431-8. [Abstract] [Full-text]
27. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission?
    Inflamm Bowel Dis, 13(4): 446-50. [Abstract] [Full-text]
28. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease.
    Inflamm Bowel Dis, 13(4): 424-30. [Abstract] [Full-text]
29. Use of infliximab in pyoderma gangrenosum.
    Australas J Dermatol, 48(2): 95-8. [Abstract] [Full-text]

© 2004-2008 Crohn's Disease Research Today. All Rights Reserved.